

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 22, 2003, 17:50:51 ; Search time 86.2893 Seconds
(without alignments)
1449.503 Million cell updates/sec

Title: US-09-978-248-2

Perfect score: 4069

Sequence: 1 MDASLEKIADFTLAEMGKNL.....KGVPHPDHDSQVGEPSLSR 788

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A. Geneseq 19Jun03.*

1: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1980.DAT.*
2: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1981.DAT.*
3: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1982.DAT.*
4: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1983.DAT.*
5: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1984.DAT.*
6: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1985.DAT.*
7: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1986.DAT.*
8: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1987.DAT.*
9: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1988.DAT.*
10: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1989.DAT.*
11: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1990.DAT.*
12: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1991.DAT.*
13: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1992.DAT.*
14: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1993.DAT.*
15: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1994.DAT.*
16: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1995.DAT.*
17: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1996.DAT.*
18: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1997.DAT.*
19: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1998.DAT.*
20: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1999.DAT.*
21: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2000.DAT.*
22: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2001.DAT.*
23: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.*
24: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	4069	100.0	788	22	AA039095
2	4069	100.0	788	23	AAE23718
3	4060	99.8	867	24	ABP52115
4	4047	99.5	820	22	AAW40881
5	2427	59.6	518	22	AAW25938
6	2089	51.3	425	22	AAW75454
7	1815	44.6	371	21	ABW57103
8	882.5	21.7	852	22	ABW58175
9	354	8.7	90	22	AA005809

10	294	7.2	58	20	AAV11922	Human 5' EST seque
11	240	5.9	476	22	ABG18289	Novel human diagno
12	196	4.8	489	23	ABF38075	Staphylococcus epi
13	195	4.8	490	14	AA34135	C.roseus TDC with
14	195	4.8	500	11	AA06829	Tryptamine. Catha
15	195	4.8	500	14	AA34133	Catharanthus roseu
16	195	4.8	500	19	AAW71745	Catharanthus roseu
17	194	4.8	76	22	AA001931	Human polypeptide
18	177.5	4.4	593	13	AAW27220	Brain GAD #2. Mus
19	171.5	4.2	493	18	AAW20065	Human GADII. protei
20	171.5	4.2	493	18	AAW22306	Human GADII. Ratt
21	170.5	4.2	506	18	AAW20064	Rat GADII. protein.
22	170.5	4.2	506	18	AAW22305	Rat GADII. Rattus
23	169.5	4.2	625	23	AAW77954	Protein of glutami
24	166.5	4.1	594	13	AAW27222	Full length islet
25	165.5	4.1	594	19	AAW74717	Amino acid sequenc
26	165.5	4.1	594	20	AAW33656	Chimeric rat GAD65
27	165.5	4.1	594	21	AAW30372	Chimeric human GAD
28	162.5	4.0	594	21	AAW57064	Glutamate decarbox
29	162.5	4.0	594	24	AA026670	Glutamic acid deca
30	161.5	4.0	594	13	AAW27221	Full length brain
31	160.5	3.9	502	23	AAE25378	Human NZMS-2 prote
32	160.5	3.9	510	22	ABW71409	Drosophila melanog
33	159.5	3.9	585	13	AAW23644	Rat GAD65 gene pro
34	153.5	3.8	509	22	AAW50244	Wheat tryptophan d
35	153.5	3.8	509	23	AAU76426	Wheat tryptophan d
36	152	3.7	335	22	AAU87366	Novel central nerv
37	151	3.7	584	19	AAW34520	Rat GAD65 protein.
38	151	3.7	584	20	AAW60118	Rat GAD65 protein
39	149	3.7	510	22	ABW71951	Drosophila melanog
40	147	3.6	847	22	ABW59917	Drosophila melanog
41	146	3.6	575	22	ABW63518	Drosophila melanog
42	145.5	3.6	585	13	AAW28756	Human pancreatic i
43	145.5	3.6	585	16	AAW71641	Human GAD. Homo s
44	145.5	3.6	585	16	AAW79105	Human glutamic aci
45	145.5	3.6	585	18	AAW35361	Human 65K-glutamic

ALIGNMENTS

RESULT 1

AAW39095

ID AAW39095 standard; Protein; 788 AA.

XX AAW39095;

AC AAW39095;

XX 22-OCT-2001 (first entry)

XX Human polypeptide SEQ ID NO 2240.

XX Human; notropoc; immunosuppressant; cytostatic; gene therapy; cancer;
XX Peripheral nervous system; neuropathy; central nervous system; CNS;
XX Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
XX amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
XX chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
XX leukaemia.

OS Homo sapiens.

XX WO200153312-A1.

PN 26-JUL-2001.

XX 26-DEC-2000; 2000WO-US34263.

XX 21-JAN-2000; 2000US-0488725.

XX 25-APR-2000; 2000US-0552317.

XX 09-JUL-2000; 2000US-0598042.

XX 19-JUL-2000; 2000US-0620312.

XX 03-AUG-2000; 2000US-0653450.

XX 14-SEP-2000; 2000US-0662191.

XX 19-OCT-2000; 2000US-0693036.

PR 29-NOV-2000; 2000US-0727344.
XX (HYSE-) HYSEQ INC.
XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
XX Wang J, Wang J, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
XX Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX WPI; 2001-442253/47.
XX N-PSDB; AAI58251.
XX Novel nucleic acids and polypeptides, useful for treating disorders
XX such as central nervous system injuries -
XX Example 4; SEQ ID NO 2240; 10078pp; English.
XX The invention relates to human nucleic acids (AAI57798-AAI61369) and
XX the encoded polypeptides (AAI38642-AAI42213) with nootropic,
XX immunosuppressant and cytostatic activity. The polynucleotides are useful
XX in gene therapy. A composition containing a polypeptide or polynucleotide
XX of the invention may be used to treat diseases of the peripheral nervous
XX system, such as peripheral nervous injuries, peripheral neuropathy and
XX localised neuropathies and central nervous system diseases, such as
XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
XX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
XX utilisation of the activities such as: immune system suppression,
XX Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
XX and thrombolytic activity, cancer diagnosis and therapy, drug screening,
XX assays for receptor activity, arthritis and inflammation, leukaemias and
XX C.N.S disorders.
XX Note: The sequence data for this patent did not form part of the printed
XX specification.
SQ Sequence 788 AA;
Query Match 100.0%; Score 4069; DB 22; Length 788;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 788; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MDASLEKIADPTLAEMGNKLEAVKMLDSQRTRENGKLIISGDIPLQSGQDMWS 60
DB 1 MDASLEKIADPTLAEMGNKLEAVKMLDSQRTRENGKLIISGDIPLQSGQDMWS 60
QY 61 ILQLVQNLHMGDEDEBPSPQIOMIGQGHMALLGHSIGAYISTLDKELKLTITILSD 120
DB 61 ILQLVQNLHMGDEDEBPSPQIOMIGQGHMALLGHSIGAYISTLDKELKLTITILSD 120
QY 121 TTLMLCRIFRYENGCAIFHEEREGLAKICRLAIHSRYEDFVVDGFNVLYNKKPVIYLSA 180
DB 121 TTLMLCRIFRYENGCAIFHEEREGLAKICRLAIHSRYEDFVVDGFNVLYNKKPVIYLSA 180
QY 181 AARPLGQYLCNQLGPPCLCRVPCNTVFGSQHMDVAFLEKLIKDDIERGLPLLLVA 240
DB 181 AARPLGQYLCNQLGPPCLCRVPCNTVFGSQHMDVAFLEKLIKDDIERGLPLLLVA 240
QY 241 NAGTAAVGHDTKICRLKELCEQYGIWHLRVEGNVLTALGTVSSVLAACKDSMTWTPG 300
DB 241 NAGTAAVGHDTKICRLKELCEQYGIWHLRVEGNVLTALGTVSSVLAACKDSMTWTPG 300
QY 301 PWLGLPAPVATLYKHDDPALTVAGLTSNKPTDKRALPLWLSQVGLDGEVERIKHA 360
DB 301 PWLGLPAPVATLYKHDDPALTVAGLTSNKPTDKRALPLWLSQVGLDGEVERIKHA 360
QY 361 COLSRLQESLKKVNYIKILVEDELSPPVVFREFQELPGSDPVFKAVPVNMTTPSGVGR 420
DB 361 COLSRLQESLKKVNYIKILVEDELSPPVVFREFQELPGSDPVFKAVPVNMTTPSGVGR 420
QY 421 ERHSCDALNRWLGEOLKQVPSAGLTVMDLBAEGTCLRFPSPLMTAAVLGTRGEDVDOLVA 480
DB 421 ERHSCDALNRWLGEOLKQVPSAGLTVMDLBAEGTCLRFPSPLMTAAVLGTRGEDVDOLVA 480
QY 481 CIESKLPVLCCTQLREEPKQEVATAGLLVVDPPNWSGIGVVRYEHANDKSKSLSDPE 540
DB 481 CIESKLPVLCCTQLREEPKQEVATAGLLVVDPPNWSGIGVVRYEHANDKSKSLSDPE 540

DB 481 CIESKLPVLCCTQLREEPKQEVATAGLLVVDPPNWSGIGVVRYEHANDKSKSLSDPE 540
QY 541 GENTHAGLLKLANELESDFKIGPEYKSMKSCLYVGMASDNVDAHELVTIATAREIE 600
DB 541 GENTHAGLLKLANELESDFKIGPEYKSMKSCLYVGMASDNVDAHELVTIATAREIE 600
QY 601 ENSRLLENMTVEVRKGIQEAQVELQKASEERLLEEGVLRQIPVVGSVLWVWFSVQALQKG 660
DB 601 ENSRLLENMTVEVRKGIQEAQVELQKASEERLLEEGVLRQIPVVGSVLWVWFSVQALQKG 660
QY 661 RTFNLTAGSLSTETPIYVYKAQAGVTLPTPGSRTKQRLPGCKPFRSLRGSALSET 720
DB 661 RTFNLTAGSLSTETPIYVYKAQAGVTLPTPGSRTKQRLPGCKPFRSLRGSALSET 720
QY 721 SSVSHIEDLEKVERLSSGPQITLEASSTEGHPCAPSQHTDTEAFQKGVPHPEDDHSQ 780
DB 721 SSVSHIEDLEKVERLSSGPQITLEASSTEGHPCAPSQHTDTEAFQKGVPHPEDDHSQ 780
QY 781 VEGPESLR 788
DB 781 VEGPESLR 788
RESULT 2
AAE23718
ID AAE23718 standard; Protein; 788 AA.
XX
AC AAE23718;
XX 10-SEP-2002 (first entry)
DT
XX
DE Human GNK interacting decarboxylase (GID).
XX
KW Human; guanine nucleotide exchange factor containing NEK-like kinase;
KW GNK; GNK interacting decarboxylase; GID; neurodegenerative disorder;
KW caspase-3; pathogenesis; immunosuppressive; neuroprotective; cancer;
KW amino acid decarboxylase domain; autoimmunity; cytostatic; enzyme.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Domain 216..395
FT /note= "Decarboxylase domain; This region is
FT specifically referred in claim 6"
FT Cleavage-site 581..584
FT /note= "Caspase-3 cleavage site"
FT Domain 585..631
FT /note= "C-terminal coiled coil domain"
XX
PN WO200233059-A2.
XX
PD 25-APR-2002.
XX
PF 17-OCT-2001; 2001WO-US322493.
XX
PR 18-OCT-2000; 2000US-241324P.
PR 16-OCT-2001; 2001US-0978248.
XX
PA (IMMV) IMMUNEX CORP.
XX
XX Holland PM, Virca GD, Bird TA, Garka K;
XX WPI; 2002-452385/48.
XX N-PSDB; AAD37980.
XX
XX GNK interacting decarboxylase, useful for detecting caspase-3 activity
XX and screening (ant)agonist for treating autoimmunity and
XX neurodegenerative disorders -
XX Claim 1; Page 13; 82pp; English.
XX
XX The invention relates to GNK (Guanine nucleotide exchange factor
XX containing NEK-like kinase) interacting decarboxylase (GID) and its

Db 1681 TTTAAATAGCCCTGAGTATATAGAGCAAGAGAGCTGCTTTATGTGCGCATGGCAGC 1740
QY 1741 GACAACTGCTGATGCTGCTGAGCTGCTGAGACACATTCGCGCCACAGCCCGGAGATAGAG 1800
Db 1741 GACAACTGCTGATGCTGCTGAGCTGCTGAGACACATTCGCGCCACAGCCCGGAGATAGAG 1800
QY 1801 GAGAACTGAGGCTTCTGGAATAACATGACAGAAAGTGTTCGGAAGGCAATTCAGGAAGCT 1860
Db 1801 GAGAACTGAGGCTTCTGGAATAACATGACAGAAAGTGTTCGGAAGGCAATTCAGGAAGCT 1860
QY 1861 CAAGTGGAGCTGACAGAGGCAAGTGTGAGAGAGGCTTCTGGAAGGCGGTGTTGCGGCAG 1920
Db 1861 CAAGTGGAGCTGACAGAGGCAAGTGTGAGAGAGGCTTCTGGAAGGCGGTGTTGCGGCAG 1920
QY 1921 ATCCCTGTAGTGGGCTCCGCTGCTGAATTTGCTTCTCCGCTCAGAGCTTTACAGAGGGA 1980
Db 1921 ATCCCTGTAGTGGGCTCCGCTGCTGAATTTGCTTCTCCGCTCAGAGCTTTACAGAGGGA 1980
QY 1981 AGAACTTTAACTTGACAGAGGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2040
Db 1981 AGAACTTTAACTTGACAGAGGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2040
QY 2041 GCACAAAGTGCAGAGGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2100
Db 2041 GCACAAAGTGCAGAGGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2100
QY 2101 CTTCCAGGCGCAGAGGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2160
Db 2101 CTTCCAGGCGCAGAGGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2160
QY 2161 AGCTGAGTCACTGAGAGGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2220
Db 2161 AGCTGAGTCACTGAGAGGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2220
QY 2221 CAGATCAGCTCGAGGCGCAGAGGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2280
Db 2221 CAGATCAGCTCGAGGCGCAGAGGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2280
QY 2281 ACCGACCGAGAGGCGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2340
Db 2281 ACCGACCGAGAGGCGCTTCTGGAAGTGTTCGGAAGGCAATTCAGGAAGCT 2340
QY 2341 GTAGAGGAGCGAGAGCTTAAAGTGA 2367
Db 2341 GTAGAGGAGCGAGAGCTTAAAGTGA 2367

RESULT 2
AAI58251
ID AAI58251 standard; cDNA; 3964 BP.
AC AAI58251;
XX AAI58251;
DT 22-OCT-2001 (first entry)
DE Human polynucleotide SEQ ID NO 454.
KW Human; nototropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia; ss.
OS Homo sapiens.
FN WO200153312-A1.
XX 26-JUL-2001.
PF 26-DEC-2000; 2000WO-US34263.
XX 21-JAN-2000; 2000US-0488725.

PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX (HYSE-) HYSEQ INC.
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang J, Xu C, Xu C, Xu AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Dmanac RT;
DR WPI; 2001-442253/47.
DR P-PSDB; AAM39095.
XX Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX Claim 1; SEQ ID NO 454; 10078pp; English.
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nototropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: immune system suppression,
CC activation/inhibition activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX Sequence 3964 BP; 1067 A; 867 C; 1037 G; 993 T; 0 other;

Query Match 100.0%; Score 2367; DB 22; Length 3964;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2367; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ATGACGCGTCCCTGGAGAGATAGCAGACCCAGCTTAGCTGAAATGGGAAAACTTG 60
Db 174 ATGACGCGTCCCTGGAGAGATAGCAGACCCAGCTTAGCTGAAATGGGAAAACTTG 233
QY 61 AAGGAGCGAGTGAAGATCTCGAGGACAGTCAAGAGAAACAGAGAGAGAAATGGAAG 120
Db 234 AAGGAGCGAGTGAAGATCTCGAGGACAGTCAAGAGAAACAGAGAGAGAAATGGAAG 293
QY 121 AAGCTCATATCCGAGATATTCAGGCGCCACTCCAGGCGAGTGGCAAGATATGATGAGC 180
Db 294 AAGCTCATATCCGAGATATTCAGGCGCCACTCCAGGCGAGTGGCAAGATATGATGAGC 353
QY 181 ATCTCCAGTGTAGTCAAGATCTCATGAGAGATGAGATGAGGAGCCCGCAGAGCCCC 240
Db 354 ATCTCCAGTGTAGTCAAGATCTCATGAGAGATGAGATGAGGAGCCCGCAGAGCCCC 413
QY 241 AGATCCAAATATGAGAGACAGGTCATATGCTTTGTTGGGACATAGTCTGGAGCT 300
Db 414 AGATCCAAATATGAGAGACAGGTCATATGCTTTGTTGGGACATAGTCTGGAGCT 473
QY 301 TATATTTCACTCTGGACAAAGAGAGTCAAGAACTTACAACTAGATCTTTTCAGAT 360
Db 474 TATATTTCACTCTGGACAAAGAGAGTCAAGAACTTACAACTAGATCTTTTCAGAT 533
QY 361 ACCACCTTATGGCTATGAGAAATTTTCAGATATGAAATGGTGTGCTTATTTCCAGAA 420
Db 534 ACCACCTTATGGCTATGAGAAATTTTCAGATATGAAATGGTGTGCTTATTTCCAGAA 593

